|
|
|
|
|
|
|
The 2026 Southeastern Section of the American Urological Association Annual Meeting
|
|
|
|
|
| Durable 24-Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Nonmuscle Invasive Bladder Cancer with CIS
|
| Shreyas Joshi, MD, MPH
|
| BOND‑003 Cohort C showed durable activity for intravesical cretostimogene grenadenorepvec in high‑risk BCG‑unresponsive NMIBC with CIS, with a 75.5% complete response rate and median duration of response still ongoing at 27.9 months. The regimen was very well tolerated, with no grade 3+ treatment‑related adverse events or treatment discontinuations, and most patients completed all protocol‑defined treatment.
|
|
|
|
|
|
| Patient Reported Outcomes Before and After Treatment with UGN-102 in Adults with Recurrent Low-Grade Intermediate-Risk Nonmuscle Invasive Bladder Cancer
|
| Trushar Patel, MD
|
| Across OPTIMA II, ATLAS, and ENVISION, UGN‑102 did not worsen overall quality of life or most symptom domains in adults with recurrent low‑grade intermediate‑risk NMIBC. Most patient‑reported scores stayed stable or improved, with only a few domain changes reaching clinically meaningful thresholds, supporting UGN‑102 as a non‑surgical option that preserves patient experience.
|
|
|
|
|
|
|
|
|
|
|
| Gemcitabine Intravesical System (TAR-200) Monotherapy in BCG-Unresponsive High-Risk NMIBC: Characterization of Recurrence, Progression, and Time to Radical Cystectomy
|
| Katie Murray, DO, MS, FACS
|
| TAR‑200 monotherapy in SunRISe‑1 Cohort 2 produced a high complete response rate in BCG‑unresponsive high‑risk NMIBC with CIS ± papillary disease, with many responses lasting beyond 12 months and most patients avoiding cystectomy at 2 years. Progression to muscle‑invasive or metastatic disease was uncommon, and the bladder‑sparing regimen was well tolerated, supporting TAR‑200 as a meaningful non‑surgical option for patients who are unwilling or unfit for cystectomy.
|
|
|
|
|
|
| Topline Results from BOND-003 Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive NMIBC
|
| Vikram Narayan, MD
|
| BOND‑003 Cohort P showed strong bladder‑sparing activity for intravesical cretostimogene grenadenorepvec in high‑risk papillary‑only BCG‑unresponsive NMIBC, with high‑grade recurrence‑free survival remaining high at 3, 6, and 9 months and responses sustained in both HG Ta and T1 subsets. The treatment was well tolerated, with no muscle‑invasive progression, no radical cystectomies, and no serious treatment‑related adverse events reported at the current follow‑up.
|
|
|
|
|
|
| Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist
|
| Joon Kyung Kim, MD
|
| In this single‑center retrospective study of 71 men with T1 NMIBC undergoing restaging TURBT, index resections done by SUO‑trained urologists were associated with less residual disease and fewer T2 upstages on re‑TURBT than those done by non‑SUO‑trained surgeons. However, once the initial TURBT was complete and included muscle, the differences largely disappeared, and short‑term recurrence at first surveillance was similar between groups.
|
|
|
|
|
|
| Physician Experiences with the Gemcitabine Intravesical System in High-Risk NMIBC: A Qualitative Study of SunRISe Trial Investigators
|
| Timothy Lyon, MD
|
| Investigators and allied staff described TAR‑200 insertion/removal as quick, straightforward, and feasible across outpatient settings, with most procedures taking under 5 minutes and cleanup/training demands being modest. They also felt TAR‑200 was better tolerated and less time‑consuming than BCG or intravesical chemotherapy, and many expected advanced practice providers to eventually perform insertions/removals in real‑world practice.
|
|
|
|
|
|
| First Results from CORE-008 Cohort A: A Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve NMIBC
|
| Shreyas Joshi, MD, PhD
|
| Cretostimogene grenadenorepvec monotherapy in CORE‑008 Cohort A showed strong early activity in high‑risk BCG‑naïve NMIBC with CIS, with an 83.7% complete response rate and no cases progressing to muscle‑invasive or metastatic disease at the reported cutoff. The regimen was very well tolerated, with no grade 3+ treatment‑related adverse events or discontinuations, supporting continued development as a bladder‑sparing, intravesical option in this setting.
|
|
|
|
|
|
| UGN-102 for Low-Grade Intermediate Risk Nonmuscle-Invasive Bladder Cancer: 5-Year Long-Term Extension Study Results from the Single-Arm, Phase 2B OPTIMA II Study
|
| William Huang, MD
|
| UGN‑102 produced durable complete responses in low‑grade intermediate‑risk NMIBC in OPTIMA II, with a median duration of response of 24.2 months among all 41 responders and 42.1 months in the long‑term follow‑up subset. The study supports UGN‑102 as a meaningful non‑surgical alternative to TURBT, with benefits sustained out to 5 years in some patients.
|
|
|
|
|
|
|
|
|
|
|
